St. Jude Reference #SJ-22-0034
Description
Researchers at St. Jude have developed an approach to disrupt ASXL1 in T cells that enables the cells to mount a robust anti-tumor or anti-viral immune response after sustained T cell stimulation. ASXL1 knock out (KO) prevents development of T cell exhaustion and hold promise for human T cell therapies infused into patients to establish a population of T cells that can sustain an anti-tumor response. Deletion of ASXL1 has the advantage over a small molecule inhibitor because disruption will be sustained as the cells divide and persist in the patient. The effect of an inhibitor disappears as the cells divide within the first week of infusion.
The researchers plan to further explore ASXL1 KO CAR T cells as a type of living drug with improved persistence and function in the setting of chronic tumor antigen and we are seeking a partner.
Keywords
Inhibit ASXL1, CAR Immunotherapy, anti-tumor, anti-viral immune response, knock out (KO), T cell exhaustion, persist
Granted patents or published applications
Patent pending
Related scientific references
Publication forthcoming
Licensing opportunities
The researchers plan to further explore ASXL1 KO CAR T cells as a type of living drug with improved persistence and function in the setting of chronic tumor antigen and we are seeking a partner.
Contact the Office of Technology Licensing (Phone: 901-595-2342, Fax: 901-595-3148) for more information.